-
1
المؤلفون: Félix Couture, Victoria Atkinson, Steven L. McCune, Alexander M. Menzies, Geoffrey T. Gibney, Andrew G. Hill, Georgina V. Long, Cuizhen Niu, Michael P. Brown, Blanca Homet Moreno, Stéphane Dalle, Steven J. O'Day, Caroline Robert, Matteo S. Carlino, Marcus O. Butler, Nageatte Ibrahim, Adi Diab, Jonathan Cebon
المصدر: Clin Cancer Res
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Skin Neoplasms, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Gastroenterology, Article, law.invention, Randomized controlled trial, law, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Adverse effect, Melanoma, business.industry, medicine.disease, Regimen, Oncology, Cohort, Toxicity, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f67743e03a6f91b67256825f8dfc5bcTest
https://doi.org/10.1158/1078-0432.ccr-21-0793Test -
2
المؤلفون: Piotr Rutkowski, Sama Ahsan, Jean-Jacques Grob, Matteo S. Carlino, James R. Anderson, Merrick I. Ross, John M. Kirkwood, Jeffrey E. Gershenwald, Caroline Robert, Jason J. Luke, Nageatte Ibrahim, Charles H. Yoon, Peter Mohr, Georgina V. Long, Alexander M.M. Eggermont, Axel Hauschild, Paolo A. Ascierto, Andrew Poklepovic, Richard A. Scolyer
المصدر: Future Oncology. 16:4429-4438
مصطلحات موضوعية: Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Adolescent, medicine.medical_treatment, Dermatologic Surgical Procedures, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Placebo, Disease-Free Survival, Placebos, Young Adult, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Internal medicine, medicine, Adjuvant therapy, Humans, Multicenter Studies as Topic, 030212 general & internal medicine, Young adult, Child, Melanoma, Neoplasm Staging, Randomized Controlled Trials as Topic, Cross-Over Studies, business.industry, General Medicine, medicine.disease, Crossover study, Clinical trial, Clinical Trials, Phase III as Topic, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, Neoplasm Recurrence, Local, business, Adjuvant
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a00dd1a28f82ed3c8216b416ba2d53Test
https://doi.org/10.2217/fon-2019-0666Test -
3
المؤلفون: Christoph Hoeller, Marie-Francoise Avril, Pietro Quaglino, François Aubin, Lars Bastholt, Takashi Inozume, Virginia Ferraresi, Michael B. Jameson, Kevin B. Kim, Oliver Bechter, Dirk Schadendorf, Kenji Yokota, Carmen Loquai, Maria-Jose Passos, Inge Marie Svane, Michele Maio, Catherine Barrow, Frank Meiss, Nageatte Ibrahim, Andrzej Mackiewicz, Phillip Parente, Tatsuya Takenouchi, Caroline Dutriaux, Piotr Rutkowski, Alfonsus J M van den Eertwegh, Paola Queirolo, Catriona M. McNeil, Peter Mohr, Felix Kiecker, Susana Puig, Friedegund Meier, Lutz Kretschmer, Alexander C.J. van Akkooi, Alex Menzies, Timothy Crook, Christian U. Blank, Suzana Matkovic, Michael C. Brown, Ragini R. Kudchadkar, Max Levin, Rüdiger Hein, Tanja Skytta, Gerald P. Linette, Clemens Krepler, Adnan Khattak, Ernest Marshall, Joseph Kerger, Oddbjorn Straume, Laurent Mortier, Jochen Utikal, Micaela Hernberg, James Larkin, Yoshio Kiyohara, Mario Mandalà, Henrik Schmidt, Daniil Stroyakovskiy, Pablo Luis Ortiz Romero, Naoya Yamazaki, John Walker, Anna Maria Di Giacomo, Lionel Geoffrois, Jean-Philippe Lacour, Caroline Robert, Vincent Descamps, Shahneen Sandhu, Gil Bar-Sela, Paul C. Nathan, Marcin Dzienis, Ralf Gutzmer, Claus Garbe, Andrey Meshcheryakov, Patrick Combemale, Martin Fehr, Guzel Mukhametshina, Helena Kapiteijn, Geke A. P. Hospers, Jun Aoi, Andrew Haydon, Rutger H. T. Koornstra, Marie-Thérèse Leccia, Sigrun Hallmeyer, Pier Francesco Ferrucci, Jean-Jacques Grob, Leonel Hernandez-Aya, Jan-Christoph Simon, Vanna Chiarion Sileni, Alain Algazi, Lidija Sekulovic, Sandrine Marreaud, Bernard Fitzharris, Jacob Schachter, Xinni Song, Wolf-Henning Boehncke, Rahima Jamal, Paul Lorigan, Maureen J.B. Aarts, Reinhard Dummer, Mike McCrystal, César Martins, Reiner Hofmann-Wellenhof, Alexander M.M. Eggermont, Carola Berking, Elaine Dunwoodie, Bernard Guillot, Michal Kicinski, Philippe Saiag, Céleste Lebbé, Thierry Lesimple, Stefan Suciu, Michal Lotem, Paula Ferreira, Mohammed M. Milhem, Laurent Machet, Patrick Terheyden, Anna Katharina Winge-Main, Peter Hersey, Jean-Francois Baurain, Axel Hauschild, Stéphane Dalle, Jean-Philippe Arnault, Paolo A. Ascierto, Gerard Groenewegen, Florent Grange, Georgina V. Long, Victoria Atkinson, Philippa Corrie, Matteo S. Carlino, Thomas Jouary, Daniel Hendler, Richard Casasola, Ashita Waterston, Jessica C. Hassel
المساهمون: University Medical Center [Utrecht], Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy], The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), N.N. Blokhin National Medical Research Center of Oncology, Edith Cowan University (ECU), Royal Marsden NHS Foundation Trust, Universitat de Barcelona (UB), Instituto de Salud Carlos III [Madrid] (ISC), Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Universitätsklinikum Essen [Universität Duisburg-Essen] (Uniklinik Essen), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Merck & Co. Inc, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Oncologie dermatologique, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Internal medicine, CCA - Cancer Treatment and quality of life
المصدر: EORTC Melanoma Group 2021, ' Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial ', The Lancet Oncology, vol. 22, no. 5, pp. 643-654 . https://doi.org/10.1016/S1470-2045Test(21)00065-6
Lancet Oncology, 22, 643-654
Lancet Oncology, 22, 5, pp. 643-654
Lancet Oncology
Lancet Oncology, 2021, 22 (5), pp.643-654. ⟨10.1016/S1470-2045(21)00065-6⟩
The Lancet Oncology, 22(5), 643-654. Lancet Publishing Groupمصطلحات موضوعية: Male, Skin Neoplasms, Medizin, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Randomized controlled trial, law, Monoclonal, 80 and over, MESH: Double-Blind Method, 030212 general & internal medicine, Neoplasm Metastasis, Humanized, Melanoma, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Adult, Aged, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Neoplasm Staging, medicine.medical_specialty, MESH: Melanoma, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Adjuvant therapy, education, Cancer staging, MESH: Humans, business.industry, MESH: Skin Neoplasms, MESH: Adult, MESH: Neoplasm Metastasis, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca46af8de45fdf5ffd9d70f717e94208Test
https://research.vumc.nl/en/publications/8aae177c-dfa8-4325-b8c2-e7b1d7339027Test -
4
المؤلفون: Peter Hersey, Jean-Jacques Grob, Blanca Homet Moreno, Omid Hamid, Erin Jensen, Tara C. Mitchell, Georgina V. Long, Jedd D. Wolchok, Ana Arance, Anthony M. Joshua, Matteo S. Carlino, Caroline Robert, Laurent Mortier, Jacob Schachter, Jeffrey S. Weber, F. Stephen Hodi, Adil Daud, Scott J. Diede, Antoni Ribas
المصدر: European journal of cancer (Oxford, England : 1990). 157
مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Post hoc, Clinical Decision-Making, Pembrolizumab, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, Stable Disease, Internal medicine, medicine, Long term outcomes, Humans, In patient, Trial registration, Immune Checkpoint Inhibitors, Melanoma, Complete response, Advanced melanoma, Aged, Neoplasm Staging, business.industry, Patient Selection, Middle Aged, Prognosis, Progression-Free Survival, Survival Rate, Oncology, Disease Progression, Female, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d36204dbb77dc73c57b42b2ef7e542Test
https://pubmed.ncbi.nlm.nih.gov/34571336Test -
5
المؤلفون: James Larkin, Ralf Gutzmer, Andrew Haydon, Paul Lorigan, Rutger H. T. Koornstra, Stéphane Dalle, Adnan Khattak, Alexander C.J. van Akkooi, Alfonsus J M van den Eertwegh, Christian U. Blank, Anna Maria Di Giacomo, Rahima Jamal, Clemens Krepler, Robert J. Lupinacci, Alexander M.M. Eggermont, Jean-Jacques Grob, Stefan Suciu, Leonel Hernandez-Aya, Caroline Robert, Matteo S. Carlino, Piotr Rutkowski, Nageatte Ibrahim, Mario Mandalà, Sandrine Marreaud, Georgina V. Long, Dirk Schadendorf, Paolo A. Ascierto, Michal Kicinski, Susana Puig, Victoria Atkinson, Shahneen Sandhu, Mikhail Lichinitser
المساهمون: Medical oncology, CCA - Cancer biology and immunology, CCA - Cancer Treatment and quality of life, AII - Cancer immunology
المصدر: Ann Transl Med
European Journal of Cancer, 116, pp. 148-157
European Journal of Cancer, 116, 148-157. Pergamon
Eggermont, A M M, Blank, C U, Mandala, M, Long, G V, Atkinson, V G, Dalle, S, Haydon, A, Lichinitser, M, Khattak, A, Carlino, M S, Sandhu, S, Larkin, J, Puig, S, Ascierto, P A, Rutkowski, P, Schadendorf, D, Koornstra, R, Hernandez-Aya, L, di Giacomo, A M, van den Eertwegh, A J M, Grob, J-J, Gutzmer, R, Jamal, R, Lorigan, P C, Lupinacci, R, Krepler, C, Ibrahim, N, Kicinski, M, Marreaud, S, van Akkooi, A C, Suciu, S & Robert, C 2019, ' Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma ', European Journal of Cancer, vol. 116, pp. 148-157 . https://doi.org/10.1016/j.ejca.2019.05.020Test
European Journal of Cancer, 116, 148-157مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Skin Neoplasms, medicine.medical_treatment, Medizin, Pembrolizumab, Metastasis, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], 0302 clinical medicine, Antineoplastic Agents, Immunological, Adjuvant therapy, AJCC-7, AJCC-8, EORTC 1325/KN-054, Melanoma, Phase III trial, Predictive factors, Prognostic factors, Adult, Aged, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Treatment Outcome, Monoclonal, Humanized, Hazard ratio, Editorial Commentary, Immunological, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Antineoplastic Agents, Ipilimumab, Antibodies, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, business.industry, Cancer, medicine.disease, 030104 developmental biology, Lymphadenectomy, business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e8c4fb38d782241aa3a6b2f75643c8Test
https://hdl.handle.net/2066/206244Test -
6
المؤلفون: Jin Zhang, Jeffrey S. Weber, James R. Anderson, Anthony M. Joshua, Adil Daud, Scot Ebbinghaus, Richard F. Kefford, Richard W. Joseph, Amita Patnaik, Peter Hersey, Wen-Jen Hwu, Omid Hamid, Caroline Robert, Tara C. Gangadhar, Antoni Ribas, Scott J. Diede, F. Stephen Hodi, Hassane M. Zarour, Roxana S. Dronca, Jedd D. Wolchok
المصدر: Journal of Clinical Oncology. 36:1668-1674
مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, law.invention, Cohort Studies, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Randomized controlled trial, law, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Metastasis, Melanoma, Aged, business.industry, Middle Aged, medicine.disease, Discontinuation, Clinical trial, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Monoclonal, Female, business, Cohort study
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc80c548aef4a43c6afca48a89a7e9fTest
https://doi.org/10.1200/jco.2017.75.6270Test -
7
المؤلفون: Jonathan Cebon, Neil Steven, Mark R. Middleton, Darcy A. Hille, Erika Richtig, Céleste Lebbé, Nageatte Ibrahim, Euan Walpole, Caroline Robert, Giuseppe Masucci, Wei Zhou, Wilson H. Miller, Teresa M. Petrella
المصدر: European Journal of Cancer. 86:115-124
مصطلحات موضوعية: Male, Cancer Research, medicine.medical_specialty, Skin Neoplasms, Time Factors, Longitudinal data, Health Status, Population, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Humans, In patient, Patient Reported Outcome Measures, 030212 general & internal medicine, education, Melanoma, Advanced melanoma, education.field_of_study, business.industry, Eortc qlq c30, Middle Aged, humanities, Surgery, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Quality of Life, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e890ea1bf10f65d9c5dbe680fbd78ba4Test
https://doi.org/10.1016/j.ejca.2017.08.032Test -
8
المؤلفون: Christian U. Blank, Scot Ebbinghaus, Reinhard Dummer, Carmen Loquai, Steven J. O'Day, Antoni Ribas, Adil Daud, Jacob Schachter, Caroline Robert, Janice M. Mehnert, Dirk Schadendorf, S. Peter Kang, Wei Zhou, Igor Puzanov, Darcy A. Hille, April K.S. Salama, Omid Hamid, Lee D. Cranmer, Alfons J.M. van den Eertwegh, Axel Hauschild
المساهمون: University of Zurich, Schadendorf, Dirk, Medical oncology, CCA - Clinical Therapy Development
المصدر: Schadendorf, D, Dummer, R, Hauschild, A, Robert, C, Hamid, O, Daud, A, van den Eertwegh, A, Cranmer, L, O'Day, S, Puzanov, I, Schachter, J, Blank, C, Salama, A, Loquai, C, Mehnert, J M, Hille, D, Ebbinghaus, S, Kang, S P, Zhou, W & Ribas, A 2016, ' Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma ', European Journal of Cancer, vol. 67, pp. 46-54 . https://doi.org/10.1016/j.ejca.2016.07.018Test
European Journal of Cancer, 67, 46-54. Pergamonمصطلحات موضوعية: Male, Cancer Research, Skin Neoplasms, Health Status, Health-related quality of life, medicine.medical_treatment, Medizin, Pembrolizumab, Carboplatin, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, 1306 Cancer Research, 030212 general & internal medicine, Melanoma, Aged, 80 and over, 10177 Dermatology Clinic, Middle Aged, Advanced melanoma, Dacarbazine, Oncology, 030220 oncology & carcinogenesis, Female, 2730 Oncology, medicine.drug, Adult, KEYNOTE-002, medicine.medical_specialty, Adolescent, Paclitaxel, 610 Medicine & health, Ipilimumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Young Adult, 03 medical and health sciences, Refractory, Internal medicine, Temozolomide, medicine, Humans, Chemotherapy, In patient, Patient Reported Outcome Measures, Aged, Patient-reported outcomes, business.industry, Cancer, EORTC QLQ-C30, medicine.disease, Surgery, Quality of Life, business, Ipilimumab-refractory melanoma
وصف الملف: 663_Schadendorf D. et al._Health-related quality of life in the randomised KEYNOTE-002_EJC 2016.pdf - application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0340a48931fc5ff52f9246c04eeed519Test
https://doi.org/10.1016/j.ejca.2016.07.018Test -
9
المؤلفون: Nageatte Ibrahim, Richard W. Joseph, Caroline Robert, Roxana S. Dronca, Adil Daud, Tara C. Mitchell, Jedd D. Wolchok, Omid Hamid, Richard F. Kefford, Jeffrey S. Weber, Antoni Ribas, Qing Zhao, Erin Jensen, Amita Patnaik, Anthony M. Joshua, F.S. Hodi, W. Hwu, Peter Hersey, Hassane M. Zarour, Sama Ahsan
المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, vol 30, iss 4
Annals of Oncologyمصطلحات موضوعية: 0301 basic medicine, Skin Neoplasms, long-term follow-up, Pembrolizumab, Kaplan-Meier Estimate, 0302 clinical medicine, Antineoplastic Agents, Immunological, Monoclonal, Humanized, Melanoma, Cancer, treatment-naive, Hematology, metastatic, Immunological, Oncology, Tolerability, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, pembrolizumab, Adult, medicine.medical_specialty, Patients, overall survival, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Time, Vaccine Related, 03 medical and health sciences, Clinical Research, Internal medicine, medicine, Overall survival, melanoma, Humans, Oncology & Carcinogenesis, Until Disease Progression, Response Evaluation Criteria in Solid Tumors, Advanced melanoma, business.industry, Evaluation of treatments and therapeutic interventions, Original Articles, medicine.disease, Discontinuation, Clinical trial, Editor's Choice, 030104 developmental biology, business, Follow-Up Studies
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4525cdc4a9d2f1fea9bc8b0ee243f7Test
https://pubmed.ncbi.nlm.nih.gov/30768148Test -
10
المؤلفون: Adil Daud, Jeroen Elassaiss-Schaap, Richard F. Kefford, Jin Zhang, Jeffrey S. Weber, Andrea Marie Perrone, Amita Patnaik, Caroline Robert, F. Stephen Hodi, Peter Hersey, Wen-Jen Hwu, Antoni Ribas, Richard W. Joseph, Jedd D. Wolchok, Tara C. Gangadhar, Omid Hamid, S. Peter Kang, Dinesh P. de Alwis, Roxana S. Dronca, Anthony M. Joshua, Keaven M. Anderson, Scot Ebbinghaus
المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 24, iss 20
Clinical Cancer Research
Clinical Cancer Research, 24(20), 4960–4967مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, Skin Neoplasms, Oncology and Carcinogenesis, Pembrolizumab, Logistic regression, Antibodies, Monoclonal, Humanized, Article, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, Internal medicine, Post-hoc analysis, Biomarkers, Tumor, Medicine, Humans, Oncology & Carcinogenesis, Melanoma, Cancer, Univariate analysis, L-Lactate Dehydrogenase, Proportional hazards model, business.industry, Hazard ratio, medicine.disease, Prognosis, 030104 developmental biology, Treatment Outcome, 030220 oncology & carcinogenesis, business
وصف الملف: application/pdf
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5259ec95070357aaab6d85752cf2a5Test
https://escholarship.org/uc/item/62m363dnTest